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Abstract
Background: Genome-wide association (GWA) studies that use population-based association approaches may identify 
spurious associations in the presence of population admixture. In this paper, we propose a novel three-stage approach 
that is computationally efficient and robust to population admixture and more powerful than the family-based 
association test (FBAT) for GWA studies with family data.
We propose a three-stage approach for GWA studies with family data. The first stage is to perform linear regression 
ignoring phenotypic correlations among family members. SNPs with a first stage p-value below a liberal cut-off (e.g. 
0.1) are then analyzed in the second stage that employs a linear mixed effects (LME) model that accounts for within 
family correlations. Next, SNPs that reach genome-wide significance (e.g. 10-6 for 34,625 genotyped SNPs in this paper) 
are analyzed in the third stage using FBAT, with correction of multiple testing only for SNPs that enter the third stage. 
Simulations are performed to evaluate type I error and power of the proposed method compared to LME adjusting for 
10 principal components (PC) of the genotype data. We also apply the three-stage approach to the GWA analyses of 
uric acid in Framingham Heart Study's SNP Health Association Resource (SHARe) project.
Results: Our simulations show that whether or not population admixture is present, the three-stage approach has no 
inflated type I error. In terms of power, using LME adjusting PC is only slightly more powerful than the three-stage 
approach. When applied to the GWA analyses of uric acid in the SHARe project of FHS, the three-stage approach 
successfully identified and confirmed three SNPs previously reported as genome-wide significant signals.
Conclusions: For GWA analyses of quantitative traits with family data, our three-stage approach provides another 
appealing solution to population admixture, in addition to LME adjusting for genetic PC.
Background
Many published genome-wide association (GWA) studies
with dense SNP markers are based on study designs with
unrelated individuals. It is well known that such designs
are prone to spurious association caused by population
admixture. A current popular solution to this problem
involves identifying axes of genetic variation via principal
components (PC) analyses with a large number of SNPs
and then adjusting for the PC in the association analysis
[1]. However, this approach may fail to adjust for popula-
tion stratification in some cases [2]. Family-based
designs, including Transmission Disequilibrium Test
(TDT) and Family-based Association Test (FBAT) [3,4]
are inherently robust to population admixture by condi-
tioning on parental genotype data. As a result, parental
data do not contribute to the power of the test, nor do the
families with both non-informative (homozygous) par-
ents. Therefore, FBAT has lower power in a homoge-
neous population than population-based association
approaches that use all genotyped and phenotyped indi-
viduals.
In the context of GWA studies with family data, we
present three basic strategies to handle a family-based
design, and then we use the three basic strategies to form
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a two-stage population-based approach, and a three-
stage family-based approach. The two-stage approach is
computationally efficient and can account for familial
relatedness, whereas the three-stage approach is addi-
tionally robust to population admixture. W e performed
simulations to evaluate the three basic strategies, the two-
stage and the three-stage approaches. We also applied
these strategies to Framingham Heart Study (FHS) SNP
Health Association Resource (SHARe) 550K GWA analy-
ses of uric acid.
Methods
Least squares regression
Least squares regression (denoted LM) is available in
many standard statistical software packages and is fast to
compute. The latter property is particularly desirable for
the latest GWA studies with growing number of SNPs
and phenotypes to analyze. The LM model can be
expressed as
where Yij and Gij are the phenotype and genotype for
the jth person in the ith family, respectively. X(.) is the cod-
ing of the genotype and εij's are independent random
measurement errors following a Gaussian distribution. β
can be estimated via maximum likelihood assuming that
Yij's are independent and the p-value of testing genetic
association is computed via two-sided t test. However, for
family-based design, Yij's from the same family are corre-
lated due to environmental and genetic effects. LM
assumes independent Yij's, which could result in inflated
type I error due to unexplained phenotype correlations in
a family.
Linear mixed effects model
Linear mixed effects (LME) model is traditionally used to
model correlated continuous outcomes. LME is a gener-
alization of LM with an additional random intercept that
can account for familial correlation in Y, i.e.
where   are subject specific
random effects correlated within a family,   is the vari-
ance due to these effects assuming homogeneous vari-
ance among different individuals, and Σi is the correlation
matrix in ith family. Similar to [5], we assume that Σi is the
matrix of the coefficient of relationships or twice the
coefficient of kinships, thus   are equivalent to
the residual polygenic effects commonly modelled in
familial aggregation or variance components linkage
analyses [6], in which the residual correlation among
family members are mostly due to small effects of many
genes shared. The p-value of testing genetic association is
computed via one-sided Wald chi-square test.
Family-based association test
FBAT statistics [4] are based on the fact that, under the
null hypothesis of no linkage and no association, condi-
tional on parental genotypes, the transmission of parental
alleles follows the Mendelian law of transmission. The
test statistic takes the following form
where Pi are the parental genotypes of the ith family,
X(Gij) is the score of the jth child's genotype in the ith fam-
ily, and E(X(Gij)|Pi) is the expected score of the child's
genotype given parental genotype data. The p-value of
testing genetic association is computed via two-sided Z
test.
Two-stage population-based approach
We propose a two-stage population-based approach for
family data. The first stage is LM ignoring the familial
correlations. The second stage uses LME on SNPs with
first stage LM p-value less than α1 (for example, α1 = 0.1).
This approach uses every genotyped and phenotyped
individual and accounts for differential pedigree struc-
tures in the data. In addition, the first stage's screening
makes this approach more efficient when applied to
GWA studies. However, it is subject to the confounding
due to population admixture.
Three-stage family-based approach
To control for population admixture, we further propose
a three-stage family-based approach. The first two stages
are identical to the two-stage approach proposed above.
In the third stage, FBAT is conducted on SNPs with sec-
ond stage p-value less than a specified threshold. FBAT p-
value with multiple testing correction (such as Bonferroni
correction) that only pertains to SNPs entered the third
stage is used as final p-value for this approach. SNPs that
did not enter the third stage are deemed as not associated
with the phenotype of interest. This approach can be
viewed as a special case of weighted FBAT approach [7],
where SNPs that did not pass first two stages are assigned
a weight of zero, and SNPs that entered third stage are
assigned equal weights that summed up to one. Figure 1
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presents a flow chart of the three-stage approach. The p-
value cut-off at each stage is used in some of our simula-
tions and n is the number of SNPs detected at the second
stage LME. When FBAT is not included, the strategy
reduces to two-stage approach.
Simulation studies
We conducted simulation studies to evaluate the type I
error and power of each of the introduced approaches.
We simulated phenotype and/or genotype data, based on
the real pedigree structures of 8,481 individuals from
1,494 pedigrees in the FHS SHARe project. Continuous
traits are randomly generated following a multivariate
normal distribution by using the program SOLAR [8],
where the trait variance contains a quantitative trait locus
(QTL), a polygenic and a residual variance component.
The correlation between a pair of individuals in a pedi-
gree due to the polygenic effect is twice their kinship
coefficient. The QTL is assumed to be di-allelic, and the
genotypes of founders are simulated under Hardy-Wein-
berg equilibrium (HWE). The offspring genotypes are
simulated under the Mendelian law of transmission. The
additive genetic model was used in both simulation and
analysis.
For the basic strategies and the two-stage approach,
combinations from the following simulation parameters
are considered for evaluating type I error rates (Tables 1,
2 and 3): 1) minor allele frequency (MAF) 0.005, 0.01,
0.05, and 0.1; 2) polygenic heritability 0.3 and 0.6; 3) traits
distributed as Normal, or non-Normal such as Chi-
squared, absolute Normal, and Log-Normal.
The validity and power of the proposed three-stage
approach can only be evaluated with genome-wide data,
thus we conducted simulations with simulated phenotype
and real SNP genotype data on chromosome 1 from the
FHS's SHARe project. We simulated 100 datasets of phe-
notypes following normal distribution. Each phenotype
dataset is combined with real genotype data of 34,265
SNPs on chromosome 1 that have passed quality control
(HWE p-value > 1e-6, call rate>95%, MAF>0.01). We
used simulated normal phenotypes with QTL variance 0,
polygenic heritability 0.3 and 0.6, to estimate type I error
rate for each studied method (Table 4). To assess power
using real genotype data, we simulated the phenotype
data by assuming SNP rs1570092 on chromosome 1 is the
QTL that explains 1% of total phenotypic variance. The
polygenic heritability is assumed to be 0.3. This SNP,
rs1570092, was selected as the QTL on the bases of 1)
HWE p-value 0.656; 2) call rate 100%; 3) MAF 0.31; and
4) in various levels of LD with some other SNPs on chro-
mosome 1. The pair-wise LD measure (r2 between any
two SNPs on chromosome 1 was computed using R
"genetics" package [9]. The SNPs were classified into five
groups based on pair-wise r2  between rs1570092 and
other chromosome 1 SNPs for studying the power under
different r2s (Table 5).
In addition, to evaluate the robustness and power of the
three-stage approach in the presence of population
admixture, we simulated phenotype and genotype of 100
admixture SNPs. We first partitioned the FHS SHARe
population into two similar-size subpopulations with dif-
ferent allele frequencies and phenotypic means. For these
100 admixture SNPs, the allele frequencies in the two
subpopulations were produced by Balding and Nichols
approach [7,10] that uses a Beta distribution with mean p
and variance p(1 - p)FST. FST, the "fixation index", was also
a scaled variance of the subpopulation allele frequencies
[11]. The combination of different allele frequencies and
phenotypic means in subpopulations creates spurious
associations in population-based association methods. In
this simulation (100 replicates), the expected allele fre-
quency p of the 100 admixture SNPs is 0.3; the QTL vari-
ance are 0 and 0.005 for assessing type I error and power,
respectively; the polygenic variance is 0.3; FST is 0.025;
and the difference in phenotypic means is created by add-
ing an offset value δ 0.25 to phenotypic value in one sub-
population. Power is evaluated separately for detecting
SNPs in LD (r2 = 0.5, 0.8, 1) with the QTL and the QTL
SNP. The software Eigenstrat [1] is used with 1) 34,625
SNPs and 100 simulated admixture SNPs, and 2) 100 sim-
u l a t e d  a d m i x t u r e  S N P s ,  t o  o b t a i n  1 0  P C  t h a t  e x p l a i n
genetic ancestry. The original simulated phenotypes and
residual phenotypes adjusting for PC obtained from 1)
and 2) are analyzed. We are specifically interested in
learning if the type I error rates of LME will be different
in analyzing the two sets of residuals.
LME analyses were conducted using the lmekin func-
tion in the R GWAF package [12] modified from the same
function in the R kinship package [13]. To test the fix
effects, GWAF package uses the Wald Chi-square test,
while kinship package uses t test. FBAT was computed
using the FBAT program [4].
Figure 1 Flow chart of the three-stage approach. P-value cut-off is 
0.1, 10-6 and 0.05/n for the first, second and third stage, respectively, 
where n is the number of SNPs detected at the second stage LME. 
When FBAT is not included, the three-stage approach reduces to two-
stage approach.Chen et al. BMC Genetics 2010, 11:40
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Results
Simulation studies
Table 1 presents the type I error rates of the three basic
strategies and the two-stage approach at 0.05 significance
level based on 10,000 replicates for a SNP with MAF 0.1,
without a QTL affecting the phenotype. For the two-stage
approach, we used two p-value cut-offs (0.1 and 0.2) at
the first stage to evaluate the type I error rates. Except for
LM, all methods have type I error rates close to 0.05 even
when the phenotype does not follow a normal distribu-
tion for the scenarios we considered. For LM, the infla-
tion increases with polygenic variance. For the two-stage
approach, when the p-value cut-off at the first stage is
more liberal, the type I error rate is slightly less conserva-
tive and closer to the type I error of LME. When consid-
ering a SNP with MAF of 0.01 and keeping other
parameters constant, the results are similar to what we
observed in Table 1 (results not shown). In brief, FBAT,
LME and the two-stage approach are robust to MAF as
low as 0.01 and to non-normality for the scenarios we
considered, and only LM has inflated type I error rates.
Table 2 presents type I error rates of the three basic
strategies and the two-stage approach at 0.05 significance
level based on 10,000 replicates for SNPs with MAF 0.1,
Table 1: Type I error estimate at alpha = 0.05 with 10,000 replicates for quantitative phenotype and single SNP genotype 
data with MAF = 0.1.
Phenotype Distribution Polygenic Variance LM LME FBAT LM-LME 1 LM-LME 2
Normal 0.3 0.084 0.051 0.050 0.049 0.051
Normal 0.6 0.115 0.052 0.049 0.046 0.050
Abs Normal 0.3 0.055 0.053 0.049 0.053 0.053
Abs Normal 0.6 0.064 0.050 0.049 0.050 0.050
Chi-square(1) 0.3 0.076 0.052 0.050 0.052 0.052
Chi-square(1) 0.6 0.104 0.049 0.051 0.045 0.047
Lognormal 0.3 0.059 0.054 0.046 0.054 0.054
Lognormal 0.6 0.066 0.049 0.047 0.049 0.049
The SNP explains 0% phenotype variation.
Normal: marginal phenotype follows the standard normal distribution
Abs Normal: marginal phenotype follows the absolute standard normal distribution
Chi-square(1): marginal phenotype follows a Chi-square distribution with 1 degree of freedom
Lognormal: marginal phenotype follows a Lognormal distribution
LM_LME1: two-stage approach with LM (p-value cut-off 0.1) at first stage
LM_LME2: two-stage approach with LM (p-value cut-off 0.2) at first stage
Table 2: Type I error estimate at alpha = 0.05 with 10,000 replicates of phenotype and a single SNP in LE with a QTL 
explaining 10% phenotype variation.
MAF Polygenic Variance LM LME FBAT LM-LME 1 LM-LME 2
0.005 0.3 0.087 0.046 0.052 0.044 0.045
0.005 0.6 0.118 0.053 0.047 0.046 0.050
0.01 0.3 0.089 0.050 0.049 0.048 0.050
0.01 0.6 0.122 0.049 0.048 0.044 0.048
0.05 0.3 0.087 0.048 0.052 0.047 0.048
0.05 0.6 0.118 0.050 0.050 0.043 0.047
0.1 0.3 0.082 0.044 0.053 0.041 0.043
0.1 0.6 0.122 0.049 0.054 0.043 0.047
The SNP explains 0% phenotype variation.
A QTL is simulated to explain 10% phenotype variation and in LE with the SNP.
Marginal phenotype distribution follows the standard normal distribution.
LM_LME1: two-stage approach with LM (p-value cut-off 0.1) at first stage
LM_LME2: two-stage approach with LM (p-value cut-off 0.2) at first stageChen et al. BMC Genetics 2010, 11:40
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0.05, 0.01 and 0.005, in linkage equilibrium (LE) with a
QTL explaining 10% phenotype variation. LM has
inflated type I error rates, while LME and FBAT have
type I error rates close to 0.05. The two-stage approach
seems to be slightly conservative, especially when using
0.1 p-value cut-off for the first stage. The results indicate
that, even though there is unexplained large QTL varia-
tion in the phenotypes, LME still has correct type I error
rates for SNPs with low MAF.
To study the relationship between FBAT and LME sta-
tistics under the null hypothesis of no association, we
present in Table 3 the correlation coefficients between
FBAT and LME statistics based on 10,000 replicates sim-
ulated similarly as in Table 1. We found FBAT and LME
statistics are highly correlated under the null hypothesis,
and the correlation is higher when LME p-value is
smaller. For the considered non-Normal phenotypes, the
results are similar, except that the correlations between
the two statistics are weaker. Because of this, it may be
i m p o s s i b l e  t o  o b t a i n  t h e  t y p e  I  e r r o r  r a t e  a n a l y t i c a l l y
using LME and FBAT sequentially to identify SNPs.
When applied to GWA analyses, our proposed three-
stage approach ensures valid global type I error by first
controlling genome-wide type I error for the first two
stages to 0.05 when there is no population admixture, and
then controlling for population admixture by using FBAT
at alpha = 0.05 via Bonferroni correction or other empiri-
cal p-value threshold for all SNPs reaching genome-wide
significance in LME.
Table 4 presents type I error rates of basic strategies,
two-stage and three-stage approaches estimated at 10-6
genome-wide significance level (Bonferroni correction)
using 100 replicates of Normal phenotypes without QTL
(MAF 0.1) effect and real genotype data of 34,265 SNPs.
The type I error rates are estimated by replicate. We use
0.01, 10-6, and 0.05/n as the p-value cut-offs for the first,
the second and the third stage, respectively, where n is the
number of SNPs entering the third stage. We choose 0.1
as the p-value cut-off at the first stage because it gives
slightly more conservative type I error rate than 0.2 does,
as shown in Tables 1 and 2. In addition, using smaller p-
value cut-off at the first stage and keeping reasonable
type I error can save computation time in GWA analyses.
O n l y  LM  h as  i n fl a t ed  t ype  I  e rr o r  r a t e s,  a n d  a l l  o t h e r
approaches have slightly conservative type I error rates,
which may be due to the conservative Bonferroni correc-
tion. Again, the inflation of LM's type I error increases
with the unexplained familial correlation.
Table 5 presents the power and type I error rates using
100 replicates of Normal phenotypes with a QTL
Table 3: Correlation coefficient between FBAT and LME statistics based on 10,000 replicates of no SNP association with a 
continuous phenotype (marginal phenotype distribution follows the standard normal distribution).
Correlation of FBAT and LME statistics at LME p-value level
MAF Polygenic Variance <.01 [.01-.05) [.05-.1) [.1-.2) [.2-.3) >.3
0.01 0.3 0.89 0.82 0.77 0.68 0.61 0.35
0.01 0.6 0.91 0.83 0.79 0.69 0.63 0.36
0.05 0.3 0.87 0.81 0.75 0.71 0.61 0.34
0.05 0.6 0.89 0.84 0.76 0.72 0.64 0.36
0.1 0.3 0.90 0.81 0.77 0.70 0.60 0.34
0.1 0.6 0.90 0.83 0.79 0.73 0.63 0.36
Table 4: Type I error estimate at alpha = 1e-6 using 100 replicates of phenotype without QTL effect and real 550K 
genotype data of 34,265 SNPs (HWE p-value > 1e-6, call rate > 95%, MAF > 0.01) on chromosome 1.
MAF Polygenic Variance LM LME FBAT LM-LME 1 Three-stage
0.1 0.3 0.22 0.01 0.02 0.01 0.01
0.1 0.6 0.78 0.01 0.02 0.01 0
Marginal phenotype distribution follows the standard normal distribution.
LM_LME1: two-stage approach with LM at first stage with p-value cut-off 0.1 and LME at second stage with p-value cut-off 1e-6.
Three-stage: LM at first stage with p-value cut-off 0.1, LME at second stage with p-value cut-off 1e-6 and FBAT at third stage with p-value cut-
off 0.05/n, where n is the number of SNPs entering the third stage.Chen et al. BMC Genetics 2010, 11:40
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(rs1570092) effect of 1% and 34,265 SNPs, classified into
five groups according to their r2 with rs1570092. The
power and type I error rates of each LD group are esti-
mated at 10-6 significance level by replicate. There is no
inflated type I error (0 <r2 ≤ 0.01 group) for all compared
methods except for LM. In general, the power increases
as r2 increases as expected, except some fluctuations are
observed in LM and FBAT, which may be due to the large
number of SNPs in the 0 <r2 ≤ 0.01 group. When r2 > 0.3,
LM, LME and the two-stage approach have 100% power
to detect the association between the tested SNP and the
simulated phenotype; while the three-stage approach and
FBAT have about 99% and 39-51% power, respectively.
The three-stage approach has shown to have similar
power as LME and to be more powerful than FBAT.
Even though the three-stage approach is slightly less
powerful than LME and the two-stage approach as shown
in Table 5, it inherits the robustness to population admix-
ture from FBAT. Therefore, we further consider popula-
tion admixture (FST  = 0.025 and δ  = 0.25) in our
simulations where the type I error and power estimates
are assessed at 10-6 significance level by replicate (Table
6). Three phenotypes are analyzed in this simulation:
"original phenotypes" = the original simulated Normal
phenotypes; "residuals (1)" = residuals from adjusting the
original simulated phenotypes for 10 Eigenstrat PC
obtained from 34,625 SNPs and 100 admixture SNPs; and
"residuals (2)" = residuals from adjusting the original sim-
ulated phenotypes for 10 Eigenstrat PC obtained from
100 admixture SNPs. Since FBAT and the three-stage
approach are robust to the population admixture, we did
not apply these two approaches to analyze residuals (1)
and (2). Inflated type I error rates are observed in all stud-
ied population-based approaches (LM, LME and two-
stage approach) when using the original phenotypes and
even residuals (1). For FBAT and the three-stage
approach, no inflated type I error rate is observed from
analyzing the original simulated phenotypes. When using
residuals (2), no inflation in type I error is observed for
LME and the two-stage approach. When estimating
power, 34,625 SNPs are not used. In general, LME and the
two-stage approach using original simulated phenotypes
and residuals (1) have similar power and are most power-
ful but with slightly inflated type I error, followed by the
three-stage approach, LME and the two-stage approach
with residuals (2), and then FBAT.
Application to GWA analyses of uric acid level
We applied the strategies to the GWA analyses of uric
acid levels in FHS SHARe project. A genome-wide scan
of Affymetrix 550K SNP GeneChip on about 9,000 sub-
jects was performed. GWA analyses using LME have
identified 3 loci SCL2A9, ABCG2 and SCL17A3 with
genome-wide significance (p-value < 5 × 10-8), and all the
loci have been replicated in two other independent
cohorts, the Rotterdam Study and the ARIC Study [14].
Here we re-analyze the residuals obtained from adjusting
multi-variables for uric acid levels using the three-stage
approach. The original FHS uric acid levels phenotype is
approximately normal distributed with mean 315.2 and
standard deviation 89.2 in μmol/l [14]. We first analyze all
550K SNPs using LM. With a p-value cut-off of 0.1,
80,527 SNPs passed the first stage and were analyzed by
LME. Among them, 150 SNPs reached the genome-wide
significance level. The 150 SNPs are located in the same
three loci identified previously by LME [14]. When using
0.05/150 as significance level for the third stage FBAT
analyses, 115 SNPs in SCL2A9 and ABCG2 reach the sig-
nificance level. If only the most significant SNPs in the
three loci (rs2231142 in ABCG2, rs16890979 in SCL2A9,
and rs1165205 in SLC17A3) are taken forward to the
FBAT analyses, where we can use 0.05/3 as the signifi-
cance level, all the three top SNPs in SCL2A9, ABCG2
Table 5: Power estimate at alpha = 1e-6 using 100 replicates of phenotype with 1% QTL (rs1570092 with MAF 0.31) effect 
and 30% of polygenic effect, and real 550K genotype data of 34,265 SNPs (HWE p-value > 1e-6, call rate > 95%, MAF > 
0.01) on chromosome 1.
LD group # SNPs in LD group LM LME FBAT LM-LME 1 Three-stage
0 <r2 ≤ 0.01 34025 0.20 0 0.01 0 0
0.01 <r2 ≤ 0.1 209 0.02 0.01 0 0.01 0
0.1 <r2 ≤ 0.3 6 0.70 0.54 0 0.54 0.50
0.3 <r2 ≤ 0.8 15 1 1 0.39 1 0.99
0.8 <r2 ≤ 1 10 1 1 0.51 1 0.99
rs1570092 explains 1% phenotype variation.
Marginal phenotype distribution follows a normal distribution with variance 1. The additive genetic effect is sqrt(0.01/2/0.31/0.69) = 0.153.
LM_LME1: two-stage approach with LM at first stage with p-value cut-off 0.1, and LME at second stage with p-value cut-off 1e-6.
Three-stage: LM at first stage with p-value cut-off 0.1, LME at second stage with p-value cut-off 1e-6 and FBAT at third stage with p-value cut-
off 0.05/n, where n is the number of SNPs entering the third stage.Chen et al. BMC Genetics 2010, 11:40
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and SCL17A3 reach the significance level. The results of
the three top SNPs are presented in Table 7.
Discussion
We have proposed a three-stage strategy to conduct
GWA analyses on quantitative traits for family data. This
strategy consists of LM as the first stage, LME accounting
for familial relatedness but without correction for admix-
ture as the second stage, and FBAT as the final stage. Sim-
ulation studies have shown that this approach is more
powerful than single stage FBAT and is robust to popula-
tion admixture.
When there is no population admixture, our simulation
results show that FBAT, LME and the two-stage approach
had correct type I error rates even for non-Normal phe-
notypes and for SNPs with MAF as low as 0.005. This
would justify the use of two-stage approach by applying
LME to the SNPs screened by LM and the benefit is the
time-saving efficiency almost without power loss in GWA
studies except power loss may occur to non-normal phe-
notypes [15]. In our simulation studies, it took 283 sec-
onds to complete LME analyses but only 2 seconds to
complete LM analyses of 100 SNPs on a single Linux pro-
cessor (2 × Dual-Core AMD Opteron(tm) Processor 2218
HE and total 12 GB RAM). So a genome-wide association
analyses of 2.5 million Hapmap SNPs will require 1965
hours (82 days) if using LME, but only 210 hours (9 days)
on such a single processor if using the two-stage
approach since about 10% SNPs are analyzed using LME
in the two stage approach. When the population admix-
ture exists, our simulation results show that the three-
stage approach inherits FBAT's robustness to population
admixture and LME's good power to detect the associ-
ated SNPs. We also found that using PC of all the SNPs in
Table 6: Type I error and power estimates in the presence of population admixture at alpha = 1e-6 using 100 replicates.
Phenotype data LM LME FBAT LM-LME 1 Three-stage
Type I error (r2 = 0) original phenotypes 0.63 0.08 0.02 0.08 0.02
residuals (1) 0.59 0.07 - 0.07 -
residuals (2) 0.13 0.01 - 0.01 -
Power r2 = 0.5 original phenotypes 0.43 0.39 0 0.39 0.31
residuals (1) 0.45 0.37 - 0.37 -
residuals (2) 0.17 0.14 - 0.14
Power r2 = 0.8 original phenotypes 0.66 0.63 0.05 0.63 0.56
residuals (1) 0.66 0.63 - 0.63 -
residuals (2) 0.57 0.47 - 0.47 -
Power QTL original phenotypes 0.81 0.85 0.11 0.85 0.83
residuals (1) 0.82 0.84 - 0.84 -
residuals (2) 0.81 0.67 - 0.67 -
Marginal phenotype distribution follows a normal distribution with variance 1. The additive genetic effect in assessing power is sqrt(0.005/
2/0.3/0.7) = 0.109.
LM_LME1: two-stage approach with LM at first stage with p-value cut-off 0.1 and LME at second stage with p-value cut-off 1e-6.
Three-stage: LM at first stage with p-value cut-off 0.1, LME at second stage with p-value cut-off 1e-6 and FBAT at third stage with p-value cut-
off 0.05/n, where n is the number of SNPs entering the third stage.
The original simulated phenotypes and the residuals adjusted for 10 PC obtained from all 34,625 SNPs on chromosome 1 and 100 admixture 
SNPs (1), and from 100 admixture SNPs (2) are analyzed. The 100 admixture simulated SNPs have expected allele frequency 0.3, FST = 0.025, 
the offset value δ = 0.25, QTL variance is 0.005, and the polygenic variation is 0.3. When estimating power, 34,265 SNPs are not used.Chen et al. BMC Genetics 2010, 11:40
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a GWA study may not always be able to adjust for the
population admixture that involves only a subset of SNPs.
Although it is not clear what pattern the admixture is
most likely to follow in a given population, it is conceiv-
able that there could be difference between subpopula-
tions in limited chromosome regions. When the
a d m i x t u r e  e f f e c t  o n l y  i n v o l v e s  a  s u b s e t  o f  S N P s ,  o u r
approach is more robust to population admixture than
LME adjusting for PC estimated using all SNPs and is
more powerful than LME adjusting for PC estimated
using admixture SNPs.
For genome-wide scan with dense SNPs, many signifi-
cant SNPs in LME analyses may be associated with a sin-
gle locus. When all of these SNPs are included in FBAT
analyses, Bonferroni correction for FBAT is apparently
too conservative. One modification of our approach is to
identify SNPs independently associated with the pheno-
type using stepwise selection or other selection scheme
among the significant SNPs detected by LME. Then only
conduct FBAT analyses on selected SNPs independently
associated with the phenotype in the LME analyses. By
doing this, Bonferroni correction for FBAT would be
much less conservative. In our application to uric acid
level GWA analysis, the modified three-stage approach
confirmed the three genome-wide significantly associ-
ated loci (SCL2A9, ABCG2 and SCL17A3) identified by
LME in FHS SHARe project.
A potential modification of the three-stage approach to
avoid power loss in FBAT is to include one more stage by
applying quantitative trait linkage disequilibrium (QTLD
[16]) to test stratification/admixture for the SNPs identi-
fied by the second stage LME. If there is no admixture,
the tested SNP may be claimed as a signal. Otherwise,
FBAT is then applied to test the SNPs with admixture for
association.
FBAT is known for the robustness against admixture
and the lack of power compared to population-based
methods. To circumvent multiple testing and improve its
power in GWA analyses, two-stage FBAT approaches
were proposed [7,17]. In brief, the first screening stage
regresses the offspring phenotype on the offspring's
expected genotype, given parental genotypes; the second
stage in [17] then applies FBAT to the best 10 SNPs from
the screening stage and the correction for multiple test-
ing is applied only to the second stage, while the second
stage in [7] ranks all SNPs based on the results from the
first stage and tests the i-th ranked SNP with the signifi-
cance level wiα, where Σwi = 1, w1  > 0 and α  is the
genome-wide significance level. [18] presents an applica-
tion of the two-stage FBAT approach of [17]. The two-
stage FBAT approach and our three-stage approach share
the similarities of 1) the initial stages are not robust to
admixture; 2) FBAT is the last stage. However, the paren-
tal phenotype data are not used in the two-stage FBAT
approach which may cause loss in power.
Even though our main interest focuses on quantitative
traits, similar strategies can be applied to dichotomous
traits, where the first stage uses logistic regression, the
second stage uses generalized estimating equations (GEE)
[19], and the third stage uses FBAT. In the second stage,
the GEE approach can be applied with an independence
working correlation matrix or an exchangeable (com-
pound symmetry) working correlation matrix and empir-
ical sandwich estimators, since GEE is known to be
robust against misspecification of the correlation struc-
ture models.
Conclusions
For GWA analyses on quantitative traits with family data,
our three-stage approach provides another appealing
method robust to population admixture, in addition to
using LME adjusting for PC.
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Table 7: Top SNP in each gene identified from the three-stage analyses of Uric acid levels in FHS SHARe project.
SNP Chr Position Gene MAF LM pval LME pval FBAT pval Direction Three-stage pval Three-stage pval 
for top SNPs
rs1165205 6 25978521 SLC17A3 0.46 3.2E-11 5.6E-10 7.1E-03 --- 1.0E+00 2.1E-02
rs2231142 4 89271347 ABCG2 0.11 2.4E-23 9.0E-20 5.6E-11 +++ 8.3E-09 1.7E-10
rs16890979 4 9531265 SLC2A9 0.23 3.4E-88 1.6E-76 8.3E-23 --- 1.2E-20 2.5E-22
1) Direction: the three signs are the direction of changes in multivariable adjusted uric acid per minor allele in the LM, LME and FBAT analyses, 
respectively.
2) Three-stage pval: Three-stage p-values adjusting for the multiple testing of all SNPs with p-value < 5 × 10-8 in the second stage.
3) Three-stage pval for top SNPs: Three-stage p-values adjusting for the multiple testing of only the top SNP in each gene among all SNPs 
with p-value < 5 × 10-8 in the second stage.Chen et al. BMC Genetics 2010, 11:40
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